Units, Clicks? Novel Diabetes Combos Need A Measurement
Executive Summary
Doses for Sanofi, Novo's insulin/GLP-1 combinations cannot be referred to simply by the insulin measurement, advisory committee members agree.
You may also be interested in...
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC
The latest drug development news and highlights from our FDA Performance Tracker.
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.